Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGkappa monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis.
Reinheit:
>99.0%
CAS Nummer:
[1792181-33-9]
Target-Kategorie:
IL Receptor/Related
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten